期刊文献+

降钙素口服制剂的研究进展 被引量:1

原文传递
导出
摘要 目的:为进一步研发降钙素口服制剂提供参考。方法:以"降钙素""口服""药效学""药动学""骨质疏松"等组合作为关键词,检索2000-2014年PubMed、中国知网期刊全文数据库和万方医学网等,对降钙素的药理活性、口服制剂的有效性、药动学性质及其影响因素等方面内容进行综述。结果:共查阅文献511篇,有效文献29篇。综述表明,降钙素能够较好地改善骨质量,亦可缓解疼痛,但现有剂型的临床应用有限。与现有的注射剂和喷鼻剂相比,口服剂型虽较易被患者接受,但尚存在体内稳定性差和生物利用度低等问题;其药动学行为亦受到饮水、饮食及给药时间等因素的影响。结论:降钙素口服制剂具有较好的发展前景,但面临的难题亦需逐步解决,才能使其得到较为广泛的应用。
出处 《中国药房》 CAS CSCD 2014年第29期2777-2780,共4页 China Pharmacy
  • 相关文献

参考文献29

  • 1侯笑然,张庆,李国坤,邱志霞,陈西敬.降钙素的研究进展[J].中国药房,2011,22(17):1617-1619. 被引量:15
  • 2Henriksen K, Bay-Jensen AC, Christiansen C, et al. Oral salmon calcitonin: pharmacology in osteoporosis[J]. Ex- pert Opin Biol Ther, 2010,10( 11 ) : 1 617.
  • 3Henriksen K, Neutzsky-Wulff AV, Bonewald LF, et al. Lo- cal communication on and within bone controls bone re- modeling[J]. Bone, 2009,44 (6):1 026.
  • 4Seeman E, Delmas PD. Bone quality: the material and str- uctural basis of bone strength and fragility[J]. N Engl J Med, 2006,354(21 ) : 2 250.
  • 5Martin T J, Seeman E. New mechanisms and targets in the treatment of bone fragility[J]. Clin Sci: Lond, 2007, 112 (2):77.
  • 6Eriksen EF, Halse J, Moen MH. New developments in the treatment of osteoporosis[J]. Acta Obstet Gynecol Scand, 2013,92(6) : 620.
  • 7李静.骨质疏松症的药物治疗新进展[J].中国疗养医学,2013,22(11):984-986. 被引量:5
  • 8Chesnut CH, Majumdar S, Newitt DC, et al. Effects of sa- lmon calcitonin on trabecular microarchitecture as deter- mined by magnetic resonance imaging: results from the QUEST study[J]. JBone Miner Res, 2005,20(9) : 1 548.
  • 9Chesnut CH, Silverman S, Andriano K, et al. A randomiz- ed trial of nasal spray salmon calcitonin in postmenopaus- al women with established osteoporosis: the prevent recur- rence of osteoporotic fractures study[J]. Am J Med, 2000, 109(4):267.
  • 10Byrjalsen I, Leeming D J, Qvist P, et al. Bone turnover and bone collagen maturation in osteoporosis: effects of anti- resorptive therapies[J]. Osteoporos lnt, 2008,19(3) :339.

二级参考文献54

  • 1陈铭,邓秋,李馨儒,刘艳.鲑鱼降钙素柔性脂质体大鼠鼻腔给药的降血钙效应[J].药学学报,2007,42(6):681-686. 被引量:9
  • 2Purdue BW, Tilakaratne N, Sexton PM. Molecular pharm- acology of the calcitonin receptor[J]. Receptors and Chan- nels, 2002,8(3-4) : 243.
  • 3Shyu JF, Shih C, Tseng CY, et al. Calcitonin induces pod- osome disassembly and detachment of osteoclasts by mod- ulating Pyk2 and Src activities[J]. Bone, 2007, 40 (5) : 1 329.
  • 4Gardner CR. Morphological analysis of osteoclastogenesis induced by RANKL in mouse bone marrow cell cultures [J]. Cell Biology International, 2007, 31 (7) : 672.
  • 5Mancini L, Paul-Clark MJ, Rosignoli G, et al. Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis[J]. Ameri- can Journal of Pathology, 2007,169 ( 3 ) : 1 018.
  • 6Gennari C. Analgesic effect of calcitonin in osteoporosis[J]. Bone, 2002,30 (5) : 67.
  • 7Pecile A. Calcitonin and relief of pain[J]. Bone Miner, 1992, 16 (3) : 187.
  • 8Braga PC. Calcitonin and its antinociceptive activity: ani- mal and human investigations 1975 -- 1992[J]. Agents and Actions, 1994,41(3-4) : 121.
  • 9Sibilia V, Pagani F, Lattuada N, et al. Amylin compared with calcitonin: competitive binding studies in rat brain and anticiceptive activity[J]. Brain Research, 2000, 854 (1-2):79.
  • 10Karsdal MA, Tanko LB, Riis B J, et al. Calcitonin is invo- lved in cartilage homeostasis: is calcitonin a treatment for OA? [J]. Osteoarthritis and Cartilage, 2006, 14 (7) : 617.

共引文献20

同被引文献36

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部